Pitavastatin Calcium
| 匹伐他汀钙 | Pitavastatin | 147526-32-7 | In-House |
| PI-5 | 3800-06-4 | In-House | |
| PI-6 | 145516-11-4 | In-House | |
| PI-7 | 121660-11-5 | In-House |
Description
Pitavastatin Calcium (NK-104 hemicalcium) is a potent hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitor. Pitavastatin Calcium (NK-104 hemicalcium) inhibits cholesterol synthesis from acetic acid with an IC50 of 5.8 nM in HepG2 cells. Pitavastatin Calcium is an efficient hepatocyte low-density lipoprotein-cholesterol (LDL-C) receptor inducer. Anti-cancer activity.
Background
Pitavastatin Calcium is a competitive inhibitor of the enzyme HMGCR (HMG-CoA reductase) results in a reduction in LDL cholesterol synthesis. Alternate studies show that pitavastatin can suppress oxygen production in endothelial cells by inhibiting NADPH oxidase. In addition, pitavastatin reduces the expression of eNOS mRNA while increasing the NO dependent response stimulated by acetylcholine and the calcium ionophore, A23187. Furthermore, pitavastatin inhibits the up-regulation of conductance calcium-activated potassium channels by lowering cholesterol levels in cells.
Storage
4°C, protect from light
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Chemical structure
Related Biological Data
Proposal 18 Quality Consistency Evaluation projects which have approved 4, and 6 projects are under approving.
Advanced international quality management system has laid solid foundation for sales.
Quality supervision runs through the whole life cycle of the product to ensure the quality and therapeutic effect.
Professional Regulatory Affairs team supports the quality demands during the application and registration.
Korea Countec Bottled Packaging Line
Taiwan CVC Bottled Packaging Line
Italy CAM Board Packaging Line
German Fette Compacting Machine
Japan Viswill Tablet Detector
DCS Control Room
